| 1 |
35626081 | How Phosphofructokinase-1 Promotes PI3K and YAP/TAZ in Cancer: Therapeutic Perspectives. | 2022 May 18 |
1 |
| 2 |
34924279 | Why may citrate sodium significantly increase the effectiveness of transarterial chemoembolization in hepatocellular carcinoma? | 2021 Dec |
3 |
| 3 |
32444674 | The Hepatic Plasma Membrane Citrate Transporter NaCT (SLC13A5) as a Molecular Target for Metformin. | 2020 May 22 |
1 |
| 4 |
31141937 | Effects of Long-Term Citrate Treatment in the PC3 Prostate Cancer Cell Line. | 2019 May 28 |
1 |
| 5 |
21698747 | Muscle-type 6-phosphofructo-1-kinase and aldolase associate conferring catalytic advantages for both enzymes. | 2011 Jun |
1 |
| 6 |
21124851 | Evolution of allosteric citrate binding sites on 6-phosphofructo-1-kinase. | 2010 Nov 23 |
4 |
| 7 |
19250982 | Calmodulin upregulates skeletal muscle 6-phosphofructo-1-kinase reversing the inhibitory effects of allosteric modulators. | 2009 Aug |
2 |
| 8 |
17229526 | Purification and kinetic properties of 6-phosphofructo-1-kinase from gilthead sea bream muscle. | 2007 Apr |
1 |
| 9 |
12974670 | Identification of C-terminal motifs responsible for transmission of inhibition by ATP of mammalian phosphofructokinase, and their contribution to other allosteric effects. | 2004 Jan 1 |
1 |
| 10 |
7929613 | Glucose fatty acid interactions and the regulation of glucose disposal. | 1994 |
1 |